Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06402201 · ClinicalTrials.gov registry record · Phase 1
First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors
A Phase 1 study of Select Advanced Solid Tumors, sponsored by CDR-Life.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 18
- Study locations
NCT06402201 is a Phase 1 study of Select Advanced Solid Tumors that is actively recruiting participants, run by CDR-Life. The registered enrollment target is 42 participants. The trial reports 18 study locations across 6 states.
The verdict
NCT06402201, a Phase 1 study of Select Advanced Solid Tumors, is actively recruiting participants, sponsored by CDR-Life.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 18
- Study locations
Study Summary
CDR404 is a highly potent and specific T-cell engaging bispecific and bivalent antibody designed for the treatment of cancers positive for the tumor-associated antigen melanoma-associated antigen 4 (MAGE-A4). This is a first-in-human study designed to evaluate the safety, tolerability, and preliminary anti-tumor activity of CDR404 in adult patients who have the appropriate germline human leukocyte antigen HLA-A\*02:01 tissue marker and whose cancer is positive for MAGE-A4.
Conditions Studied
Interventions
- BIOLOGICAL CDR404
Study Locations (18)
Other
- Universitair Ziekenhuis Antwerpen - Antwerp
- Institut Jules Bordet - Brussels
- Cliniques Universitaires Saint-Luc, UCL Ouvain - Brussels
- Universitair Ziekenhuis Gent - Ghent
- Rigshospitalet - Copenhagen
- Istituto Clinico Humanitas - Milan
- Isituto Europeo di Oncologia (IEO) - Milan
- Hospital Universitari Vall d'Hebron - Barcelona
- Institut Catala d'Oncologia, L'Hospitalet de Llobregat (ICO) - Barcelona
- Hospital 12 de Octubre - Madrid
- START Madrid - Madrid
- Hospital Universitari i Politecnic La Fe - Valencia
- Instituto de Investigacion Sanitaria (INCLIVA) - Valencia
Florida
- University of Miami - Miami
Michigan
- University of Michigan - Ann Arbor
Oregon
- Providence Cancer Institute - Portland
Pennsylvania
- Pennsylvania Hospital - Philadelphia
London
- Royal Marsden Hospital - Sutton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2024-05-24 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06402201
The ClinicalTrials.gov registry entry for NCT06402201 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CDR-Life, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Select Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which CDR404 is the first listed.
NCT06402201 reports 18 study locations spanning 6 distinct geographic areas - top geographies include Other, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT06402201 about?
NCT06402201 is a clinical study titled "First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors". CDR404 is a highly potent and specific T-cell engaging bispecific and bivalent antibody designed for the treatment of cancers positive for the tumor-associated antigen melanoma-associated antigen 4 (MAGE-A4). This is a first-in-human study designed to evaluate the safety, tolerability, and prelimina...
What is the current status of trial NCT06402201?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2024-05-24. Estimated completion is 2027-12-31.
What conditions does trial NCT06402201 study?
This clinical trial studies the following conditions: Select Advanced Solid Tumors.
What interventions are being tested in trial NCT06402201?
The interventions under investigation include: CDR404 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06402201?
This trial is sponsored by CDR-Life, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06402201 being conducted?
This trial has 18 study locations across Florida, Michigan, Oregon, Pennsylvania, London. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Select Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.